Intravitreal (IVT) Injectable Market
Intravitreal (IVT) Injectable Market Study by Anti-VEGF, Corticosteroids, Antibiotics, Antivirals, and Antifungal for Diabetic Retinopathy, Macular Degeneration, and Others from 2024 to 2034
Analysis of Intravitreal (IVT) Injectable Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Intravitreal (IVT) Injectable Market Outlook
The intravitreal (IVT) injectable market size is expected to be valued at US$ 17,565.4 million in 2024. Sales of intravitreal (IVT) injectables are projected to rise at a CAGR of 4.2% from 2024 to 2034. The market is expected to be worth US$ 26,526.1 million by 2034.
The demand for intravitreal injectables is growing due to advancements in pharmaceutical delivery technologies and an increase in the prevalence of eye disorders. The aging population and the growing desire for low-risk, effective treatment options are fueling the intravitreal (IVT) injectable market expansion.
The development of sustained-release implants, biodegradable microspheres, and intelligent drug delivery systems are stimulating growth in the intravitreal (IVT) injectable market. These advancements are intended to increase medication efficacy, decrease injection frequency, and improve patient compliance.
Advancements in targeted therapies and personalized medicine, which enable accurate and efficient treatment of eye ailments, are further contributing to the market’s growth. Increased research and development efforts to investigate novel treatment alternatives and broaden the indications for IVT injectables are also adding up to the increasing market value.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 17,565.4 million |
| Forecasted Market Value (2034F) | US$ 26,526.1 million |
| Global Market Growth Rate (2024 to 2034) | 4.2% |
| Corticosteroids Segment Growth Rate (2024 to 2034) | 5.1% |
| Retinal Vein Occlusions Segment Growth Rate (2024 to 2034) | 4.7% |
| North America Market Share (2024) | 3.4% |
| East Asia Market Share (2024) | 6.6% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Facets are Catalyzing the Growth of the Intravitreal Injectable Industry?
“Development of Targeted Therapies and Personalized Medicines”
The development of sustained-release implants, biodegradable microspheres, and smart drug delivery systems are contributing to the growth of the market. These advancements are responsible for increasing medication efficacy, decreasing injection frequency, and improving patient compliance.
The development of targeted therapies and personalized medicine and the adoption of combination therapies are fueling the demand for intravitreal injectables. Rising Focus on research and development to investigate novel treatment alternatives are bolstering the market’s growth.
What are the Factors Inhibiting Growth in the Intravitreal Injection Market?
“High Cost of Intravitreal Injectables Restricting Market Growth”
The clinical trials and research and development related to intravitreal injectables are costly and resource-intensive. High development expenditures are a significant obstacle that inhibits many intravitreal (IVT) injectable vendors from introducing novel items to the market. The adoption of intravitreal injectables can be affected by adverse effects or safety issues.
The market demand can be severely affected by limited insurance coverage and reimbursement restrictions. This is expected to hinder the market as patients and healthcare providers struggle to secure coverage for these treatments.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
The intravitreal (IVT) injectable market in North America is expected to increase at a CAGR of 3.4% until 2034. The primary catalyst of the spike is the increased demand for IVT injectables in major markets, particularly the United States and Canada. By 2034, the United States is set to command the leading share of 92.4% of the regional market.
The IVT injectable market in East Asia is expected to develop at a robust CAGR of 6.6% through 2034. China is the most lucrative market in East Asia, accounting for a share of 47.9%. The growing significance and geographic diversity of the market are expected to generate significant opportunities for established players and new entrants.
What is Fueling Demand for Intravitreal (IVT) Injectables in North America?
“Growing Prevalence of Retinal Disorders in North America”
An aging population and an increase in the prevalence of retinal diseases are the main factors influencing the United States' intravitreal (IVT) injectable market expansion. The flourishing market demand is attributed to the rising use of cutting-edge treatment alternatives and a robust healthcare system.
Patient awareness campaigns and educational initiatives propel the demand for intravitreal therapy, which is crucial in prompt diagnosis and intervention. In 2024, the United States is expected to attain a 93.3% market share.
| Attributes | Details |
|---|---|
| United States Market CAGR | 3.3% |
| United States Market Size (2024) | US$ 9,663 million |
| Canada Market CAGR | 4.4% |
| Canada Market Size (2024) | US$ 510 million |
Age-related macular degeneration (AMD) is becoming common in Canada, contributing to the market expansion. Raising awareness through public health initiatives and highlighting early detection and routine eye examination results in a proactive approach to retinal health, driving the market in Canada. In 2024, Canada is expected to secure a 4.9% market share.
Which Aspects are Influencing the Asia Pacific Intravitreal (IVT) Injectable Market?
“Rising AMD and Diabetic Retinopathy Cases in Asia Pacific”
Diabetic retinopathy has become prevalent in the rising aging population of China, which is contributing to the growth of the market for efficient retinal treatments. In China, telemedicine usage and digital health initiatives are improving, increasing patient education and involvement, which is critical for early diagnosis and prompt treatment of retinal problems. China is expected to acquire a market share of 47.4% in 2024.
| Attributes | Details |
|---|---|
| China Market CAGR | 6.7% |
| China Market Size (2024) | US$ 790 million |
| Japan Market CAGR | 6.6% |
| Japan Market Size (2024) | US$ 578 million |
The market in Japan is stimulated by a rapidly aging population and a high prevalence of age-related macular degeneration (AMD), which has created an enormous demand for novel and effective retinal treatments. The adoption of intravitreal injectables is influenced by the incorporation of artificial intelligence and data analytics into Japan's healthcare system, which is helping to facilitate early diagnosis and customized treatment plans for retinal illnesses. Japan is expected to garner a market share of 34.7% in 2024.
Category-wise Outlook
According to the drug class, the anti-VEGF segment is projected to account for 87.6% of the market share. The macular degeneration segment of the indication category is set to dominate the market with a 31.5% share. The diabetic retinopathy segment is expected to hold a share of 30.3% of the market.
The hospital pharmacies segment is poised to have a dominant share of 35.6% of the market based on distribution channels. The retail pharmacies segment is expected to achieve a 24% market share.
Which Drug Class is Leading the Intravitreal Injectable Market?
“Anti-VEGF Segment's Widespread Adoption in Retinal Care”
| Anti-VEGF | Details |
|---|---|
| Market Size (2024) | US$ 15,417.4 million |
| Market Share (2024) | 87.8% |
The rising incidence of retinal disorders and the established therapeutic benefits of anti-VEGF drugs drive the market forward. In 2024, the anti-VEGF segment is expected to account for 87.8% of the intravitreal (IVT) injectable market by drug class. Since anti-VEGF medications effectively treat neovascular illnesses by preventing aberrant blood vessel formation in the eye, they hold a dominant share in the intravitreal injectable market.
What is Propelling Sales of Intravitreal Injectables for Treating Macular Degeneration?
“Clinical Efficacy and Established Treatment Protocols Favor Adoption of IVT Injectables”
| Macular Degeneration | Details |
|---|---|
| Market Size (2024) | US$ 5,818.3 million |
| Market Share (2024) | 33.1% |
The growing trend of developing treatments for age-related ocular illnesses is consistent with the increased adoption of IVT injectables in treating macular degeneration. The market is placing more emphasis on this indication due to the growing global burden of vision impairment linked to macular degeneration.
In 2024, the macular degeneration segment is expected to capture 33.1% of the intravitreal (IVT) injectable market by indication. IVT injectables are rising in demand for the treatment of macular degeneration due to improved awareness and early diagnosis.
What Makes Hospital Pharmacies the Frontrunner in the IVT Injectable Market?
“Hospitals Provide Sterile Environments Crucial for Intravitreal Drug Handling.”
| Hospital Pharmacies | Details |
|---|---|
| Market Size (2024) | US$ 6,326.3 million |
| Market Share (2024) | 36.0% |
Hospital pharmacies are recommended for providing intravitreal injections since patients who receive them frequently need close monitoring and prompt medical intervention. The demand for intravitreal injectables is expected to increase because hospital pharmacies are staffed by skilled healthcare personnel capable of managing their complexities.
In 2024, hospital pharmacies are expected to account for 36% of the market share, based on the distribution channel. Hospitals can quickly handle crises and adverse reactions, protecting patients during treatment processes.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Analysis
The market for intravitreal (IVT) injectables is characterized by fierce competition among significant firms attempting to meet the increasing need for novel therapies for various ocular ailments. Leading intravitreal injectable providers and promising startups are actively engaged in research and development to launch innovative IVT injectables.
The rising prevalence of age-related macular degeneration and retinal diseases is stimulating the market. Regulatory approvals, safety profiles, and effectiveness are essential elements that impact competition.
The intravitreal (IVT) injectable manufacturers are looking to increase their market share. They are focusing on partnerships, collaborations, and strategic acquisitions as essential strategies. The dynamic landscape is influenced by ongoing technological breakthroughs and a focus on patient-centric solutions.
Notable Advancements
- In October 2021, Bausch + Lomb and Clearside Biomedical, Inc. introduced XIPERE, a suprachoroidal solution containing triamcinolone acetonide, which has received FDA approval for the treatment of macular edema associated with uveitis.
- In July 2018, Roche announced the first-ever successful phase II research results of a long-acting delivery device to treat neovascular age-related macular degeneration (AMD).
- The United States Food and Drug Administration (FDA) authorized Regeneron Pharmaceuticals, Inc.'s EYLEA® (aflibercept) Injection in August 2018.
Segmentation of Intravitreal (IVT) Injectable Market Research
-
By Drug Class :
- Anti-VEGF
- Corticosteroids
- Antibiotics
- Antivirals
- Antifungal
-
By Indication :
- Diabetic Retinopathy
- Macular Degeneration
- Endophthalmitis
- Retinal Vein Occlusions
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Others
-
By Region :
- North America
- East Asia
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- Middle East and Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019-2023 and Forecast, 2024-2034 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2019-2023 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2024-2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Indication 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Indication, 2019-2023 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Indication, 2024-2034 5.3.1. Macular Degeneration 5.3.2. Diabetic Retinopathy 5.3.3. Retinal Vein Occlusion 5.3.4. Endophthalmitis 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Indication, 2019-2023 5.5. Absolute $ Opportunity Analysis By Indication, 2024-2034 6. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Drug Class 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Drug Class, 2019-2023 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Drug Class, 2024-2034 6.3.1. Anti-VEGF 6.3.2. Corticosteroids 6.3.3. Antibiotics 6.3.4. Antivirals 6.3.5. Antifungals 6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019-2023 6.5. Absolute $ Opportunity Analysis By Drug Class, 2024-2034 7. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2019-2023 7.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2024-2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019-2023 and Forecast 2024-2034, By Country 8.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023 8.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024-2034 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Indication 8.2.3. By Drug Class 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Indication 8.3.3. By Drug Class 8.4. Key Takeaways 9. Latin America Market Analysis 2019-2023 and Forecast 2024-2034, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024-2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Indication 9.2.3. By Drug Class 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Indication 9.3.3. By Drug Class 9.4. Key Takeaways 10. Western Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024-2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Indication 10.2.3. By Drug Class 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Indication 10.3.3. By Drug Class 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024-2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Indication 11.2.3. By Drug Class 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Indication 11.3.3. By Drug Class 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019-2023 and Forecast 2024-2034, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024-2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Indication 12.2.3. By Drug Class 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Indication 12.3.3. By Drug Class 12.4. Key Takeaways 13. East Asia Market Analysis 2019-2023 and Forecast 2024-2034, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024-2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Indication 13.2.3. By Drug Class 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Indication 13.3.3. By Drug Class 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2034, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2019-2023 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2024-2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Indication 14.2.3. By Drug Class 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Indication 14.3.3. By Drug Class 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2023 15.1.2.1. By Indication 15.1.2.2. By Drug Class 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2023 15.2.2.1. By Indication 15.2.2.2. By Drug Class 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2023 15.3.2.1. By Indication 15.3.2.2. By Drug Class 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2023 15.4.2.1. By Indication 15.4.2.2. By Drug Class 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2023 15.5.2.1. By Indication 15.5.2.2. By Drug Class 15.6. U.K. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2023 15.6.2.1. By Indication 15.6.2.2. By Drug Class 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2023 15.7.2.1. By Indication 15.7.2.2. By Drug Class 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2023 15.8.2.1. By Indication 15.8.2.2. By Drug Class 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2023 15.9.2.1. By Indication 15.9.2.2. By Drug Class 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2023 15.10.2.1. By Indication 15.10.2.2. By Drug Class 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2023 15.11.2.1. By Indication 15.11.2.2. By Drug Class 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2023 15.12.2.1. By Indication 15.12.2.2. By Drug Class 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2023 15.13.2.1. By Indication 15.13.2.2. By Drug Class 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2023 15.14.2.1. By Indication 15.14.2.2. By Drug Class 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2023 15.15.2.1. By Indication 15.15.2.2. By Drug Class 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2023 15.16.2.1. By Indication 15.16.2.2. By Drug Class 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2023 15.17.2.1. By Indication 15.17.2.2. By Drug Class 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2023 15.18.2.1. By Indication 15.18.2.2. By Drug Class 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2023 15.19.2.1. By Indication 15.19.2.2. By Drug Class 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2023 15.20.2.1. By Indication 15.20.2.2. By Drug Class 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2023 15.21.2.1. By Indication 15.21.2.2. By Drug Class 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2023 15.22.2.1. By Indication 15.22.2.2. By Drug Class 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2023 15.23.2.1. By Indication 15.23.2.2. By Drug Class 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Indication 16.3.3. By Drug Class 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Alcon Pharmaceuticals 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Novartis 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Regeneron Pharmaceuticals Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Allergan 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Alimera Sciences 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Bristol Myers Squibb 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Bausch And Lomb 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. F. Hoffmann-La Roche 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Thrombogenics 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Valeant Pharmaceuticals International 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Million) Forecast by Region, 2019-2034
Table 02: Global Market Volume (Units) Forecast by Region, 2019-2034
Table 03: Global Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 04: Global Market Volume (Units) Forecast by Indication, 2019-2034
Table 05: Global Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 06: Global Market Volume (Units) Forecast by Drug Class, 2019-2034
Table 07: North America Market Value (US$ Million) Forecast by Country, 2019-2034
Table 08: North America Market Volume (Units) Forecast by Country, 2019-2034
Table 09: North America Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 10: North America Market Volume (Units) Forecast by Indication, 2019-2034
Table 11: North America Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 12: North America Market Volume (Units) Forecast by Drug Class, 2019-2034
Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2019-2034
Table 14: Latin America Market Volume (Units) Forecast by Country, 2019-2034
Table 15: Latin America Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 16: Latin America Market Volume (Units) Forecast by Indication, 2019-2034
Table 17: Latin America Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 18: Latin America Market Volume (Units) Forecast by Drug Class, 2019-2034
Table 19: Western Europe Market Value (US$ Million) Forecast by Country, 2019-2034
Table 20: Western Europe Market Volume (Units) Forecast by Country, 2019-2034
Table 21: Western Europe Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 22: Western Europe Market Volume (Units) Forecast by Indication, 2019-2034
Table 23: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 24: Western Europe Market Volume (Units) Forecast by Drug Class, 2019-2034
Table 25: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019-2034
Table 26: Eastern Europe Market Volume (Units) Forecast by Country, 2019-2034
Table 27: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 28: Eastern Europe Market Volume (Units) Forecast by Indication, 2019-2034
Table 29: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 30: Eastern Europe Market Volume (Units) Forecast by Drug Class, 2019-2034
Table 31: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019-2034
Table 32: South Asia and Pacific Market Volume (Units) Forecast by Country, 2019-2034
Table 33: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 34: South Asia and Pacific Market Volume (Units) Forecast by Indication, 2019-2034
Table 35: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 36: South Asia and Pacific Market Volume (Units) Forecast by Drug Class, 2019-2034
Table 37: East Asia Market Value (US$ Million) Forecast by Country, 2019-2034
Table 38: East Asia Market Volume (Units) Forecast by Country, 2019-2034
Table 39: East Asia Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 40: East Asia Market Volume (Units) Forecast by Indication, 2019-2034
Table 41: East Asia Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 42: East Asia Market Volume (Units) Forecast by Drug Class, 2019-2034
Table 43: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019-2034
Table 44: Middle East and Africa Market Volume (Units) Forecast by Country, 2019-2034
Table 45: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2019-2034
Table 46: Middle East and Africa Market Volume (Units) Forecast by Indication, 2019-2034
Table 47: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2019-2034
Table 48: Middle East and Africa Market Volume (Units) Forecast by Drug Class, 2019-2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Million) by Indication, 2024-2034
Figure 02: Global Market Value (US$ Million) by Drug Class, 2024-2034
Figure 03: Global Market Value (US$ Million) by Region, 2024-2034
Figure 04: Global Market Value (US$ Million) Analysis by Region, 2019-2034
Figure 05: Global Market Volume (Units) Analysis by Region, 2019-2034
Figure 06: Global Market Value Share (%) and BPS Analysis by Region, 2024-2034
Figure 07: Global Market Y-o-Y Growth (%) Projections by Region, 2024-2034
Figure 08: Global Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 09: Global Market Volume (Units) Analysis by Indication, 2019-2034
Figure 10: Global Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 11: Global Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 12: Global Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 13: Global Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 14: Global Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 15: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 16: Global Market Attractiveness by Indication, 2024-2034
Figure 17: Global Market Attractiveness by Drug Class, 2024-2034
Figure 18: Global Market Attractiveness by Region, 2024-2034
Figure 19: North America Market Value (US$ Million) by Indication, 2024-2034
Figure 20: North America Market Value (US$ Million) by Drug Class, 2024-2034
Figure 21: North America Market Value (US$ Million) by Country, 2024-2034
Figure 22: North America Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 23: North America Market Volume (Units) Analysis by Country, 2019-2034
Figure 24: North America Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 25: North America Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 26: North America Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 27: North America Market Volume (Units) Analysis by Indication, 2019-2034
Figure 28: North America Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 29: North America Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 30: North America Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 31: North America Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 32: North America Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 34: North America Market Attractiveness by Indication, 2024-2034
Figure 35: North America Market Attractiveness by Drug Class, 2024-2034
Figure 36: North America Market Attractiveness by Country, 2024-2034
Figure 37: Latin America Market Value (US$ Million) by Indication, 2024-2034
Figure 38: Latin America Market Value (US$ Million) by Drug Class, 2024-2034
Figure 39: Latin America Market Value (US$ Million) by Country, 2024-2034
Figure 40: Latin America Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 41: Latin America Market Volume (Units) Analysis by Country, 2019-2034
Figure 42: Latin America Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 43: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 44: Latin America Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 45: Latin America Market Volume (Units) Analysis by Indication, 2019-2034
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 49: Latin America Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 50: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 51: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 52: Latin America Market Attractiveness by Indication, 2024-2034
Figure 53: Latin America Market Attractiveness by Drug Class, 2024-2034
Figure 54: Latin America Market Attractiveness by Country, 2024-2034
Figure 55: Western Europe Market Value (US$ Million) by Indication, 2024-2034
Figure 56: Western Europe Market Value (US$ Million) by Drug Class, 2024-2034
Figure 57: Western Europe Market Value (US$ Million) by Country, 2024-2034
Figure 58: Western Europe Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 59: Western Europe Market Volume (Units) Analysis by Country, 2019-2034
Figure 60: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 61: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 62: Western Europe Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 63: Western Europe Market Volume (Units) Analysis by Indication, 2019-2034
Figure 64: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 65: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 66: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 67: Western Europe Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 68: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 69: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 70: Western Europe Market Attractiveness by Indication, 2024-2034
Figure 71: Western Europe Market Attractiveness by Drug Class, 2024-2034
Figure 72: Western Europe Market Attractiveness by Country, 2024-2034
Figure 73: Eastern Europe Market Value (US$ Million) by Indication, 2024-2034
Figure 74: Eastern Europe Market Value (US$ Million) by Drug Class, 2024-2034
Figure 75: Eastern Europe Market Value (US$ Million) by Country, 2024-2034
Figure 76: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 77: Eastern Europe Market Volume (Units) Analysis by Country, 2019-2034
Figure 78: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 79: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 80: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 81: Eastern Europe Market Volume (Units) Analysis by Indication, 2019-2034
Figure 82: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 83: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 84: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 85: Eastern Europe Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 88: Eastern Europe Market Attractiveness by Indication, 2024-2034
Figure 89: Eastern Europe Market Attractiveness by Drug Class, 2024-2034
Figure 90: Eastern Europe Market Attractiveness by Country, 2024-2034
Figure 91: South Asia and Pacific Market Value (US$ Million) by Indication, 2024-2034
Figure 92: South Asia and Pacific Market Value (US$ Million) by Drug Class, 2024-2034
Figure 93: South Asia and Pacific Market Value (US$ Million) by Country, 2024-2034
Figure 94: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 95: South Asia and Pacific Market Volume (Units) Analysis by Country, 2019-2034
Figure 96: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 97: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 98: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 99: South Asia and Pacific Market Volume (Units) Analysis by Indication, 2019-2034
Figure 100: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 101: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 102: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 103: South Asia and Pacific Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 104: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 105: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 106: South Asia and Pacific Market Attractiveness by Indication, 2024-2034
Figure 107: South Asia and Pacific Market Attractiveness by Drug Class, 2024-2034
Figure 108: South Asia and Pacific Market Attractiveness by Country, 2024-2034
Figure 109: East Asia Market Value (US$ Million) by Indication, 2024-2034
Figure 110: East Asia Market Value (US$ Million) by Drug Class, 2024-2034
Figure 111: East Asia Market Value (US$ Million) by Country, 2024-2034
Figure 112: East Asia Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 113: East Asia Market Volume (Units) Analysis by Country, 2019-2034
Figure 114: East Asia Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 115: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 116: East Asia Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 117: East Asia Market Volume (Units) Analysis by Indication, 2019-2034
Figure 118: East Asia Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 119: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 120: East Asia Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 121: East Asia Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 122: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 123: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 124: East Asia Market Attractiveness by Indication, 2024-2034
Figure 125: East Asia Market Attractiveness by Drug Class, 2024-2034
Figure 126: East Asia Market Attractiveness by Country, 2024-2034
Figure 127: Middle East and Africa Market Value (US$ Million) by Indication, 2024-2034
Figure 128: Middle East and Africa Market Value (US$ Million) by Drug Class, 2024-2034
Figure 129: Middle East and Africa Market Value (US$ Million) by Country, 2024-2034
Figure 130: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019-2034
Figure 131: Middle East and Africa Market Volume (Units) Analysis by Country, 2019-2034
Figure 132: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024-2034
Figure 133: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024-2034
Figure 134: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2019-2034
Figure 135: Middle East and Africa Market Volume (Units) Analysis by Indication, 2019-2034
Figure 136: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2024-2034
Figure 137: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2024-2034
Figure 138: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2019-2034
Figure 139: Middle East and Africa Market Volume (Units) Analysis by Drug Class, 2019-2034
Figure 140: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034
Figure 141: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034
Figure 142: Middle East and Africa Market Attractiveness by Indication, 2024-2034
Figure 143: Middle East and Africa Market Attractiveness by Drug Class, 2024-2034
Figure 144: Middle East and Africa Market Attractiveness by Country, 2024-2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What was the Value of the IVT Injectable Market in 2019?
The global intravitreal injectable market was worth US$ 13,950.1 million in 2019.
What is the Sales Outlook for Intravitreal (IVT) Injectables in 2024?
The sales of intravitreal (IVT) injectables are likely to be valued at US$ 17,565.4 million in 2024.
What is the Demand Forecast for IVT Injectables by 2034?
The demand for intravitreal (IVT) injectables is projected to reach a market value of US$ 26,526.1 million by 2034.
What is the Growth Projection for the Intravitreal (IVT) Injectable Market?
The adoption of intravitreal (IVT) injectables is projected to rise at a CAGR of 4.2% from 2024 to 2034.
At What CAGR is the IVT Injectable Market in North America Predicted to Develop?
The North American intravitreal injectable market is forecasted to expand at a CAGR of 3.4% from 2024 to 2034.
At What CAGR is the Intravitreal (IVT) Injectable Market in East Asia Predicted to Grow?
The East Asia intravitreal injectable market is forecasted to expand at a CAGR of 6.6% through 2034.
Intravitreal (IVT) Injectable Market